Surrey’s Proteome bags ‘substantial contract’ with US pharma firm

Cobham-based Proteome Sciences has secured a ‘substantial contract’ to analyse samples for a clinical trial led by a US biopharmaceutical company – an existing client.

The contract is valued at more than $1 million, with a significant portion of the work expected to be completed in the current financial year.

Richard Dennis, chief commercial officer at Proteome, said: “In April 2024, we announced the first contract from this customer and commented that we expected additional contracts to be received from them in the near future.

“This contract represents a further targeted assay that we’ll perform under good clinical laboratory practice (GCLP) compliance to monitor drug performance in an ongoing clinical trial.

“As in 2024, we’re seeing increasing interest for GCLP work from other major biopharma clients in both the US and Europe and expect additional orders to follow in 2025.”

Proteome Sciences opened a new lab in San Diego, California last January, bolstering its presence in the US.